Skip to main content
Janssen Research & Development, LLC released this advisory committee briefing document on February 12, 2019 in regards to eskatamine. Eskatamine nasal spray is a novel product developed by Janssen Research & Development for the indication of treatment-resistant depression (TRD). The briefing document provides three levels of review, including: an executive overview that provides a narrative summarizing the TRD, need for novel treatments, key development program characteristics for esketamine nasal spray, study results, and conclusions; detailed summaries in support of the executive overview; and appendices for additional and more detailed information to complement the sections in the core document.   . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase A Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!


Support Request

Need help now?

Call our toll-free phone number 877-350-6463